LAUREN P SILVERNAIL
CIK 1225755 · See Remarks · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$892.4K
Companies
7
Total Filings
71
Lifetime Open-Market Net
-$3.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HROW | Director | 1,000 | $38.68 | $38.7K | $31.0K | 2 | 2026-06-22 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $0 | 3 | 2026-02-10 |
| HARROW, INC. (HROWM) Delisted | Director | — | $26.03 | — | $0 | 3 | 2025-06-24 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 4 | 2024-03-11 |
| EOLS | See Remarks | 141,571 | $6.03 | $853.7K | -$1.03M | 12 | 2022-05-18 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO & CBO | 65,497 | $3.65 | $239.1K | -$2.31M | 25 | 2018-05-24 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Chief Financial Officer | 177,709 | — | — | $21.4K | 21 | 2012-05-10 |
Recent Filings · Page 4 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-30 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −990 | -$33.2K | EDGAR |
| 2018-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Other (J) | +443 | $10.2K | EDGAR |
| 2017-12-28 | Revance Therapeutics, Inc. (RVNC) Delisted | Exer (M) | +17,506 | $152.3K | EDGAR |
| 2017-11-09 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | — | -$181.3K | EDGAR |
| 2017-10-16 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −11,164 | -$297.8K | EDGAR |
| 2017-07-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Other (J) | +604 | $11.1K | EDGAR |
| 2017-05-31 | Revance Therapeutics, Inc. (RVNC) Delisted | Exer (M) | +23,000 | $200.1K | EDGAR |
| 2017-05-24 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −1,793 | -$36.2K | EDGAR |
| 2017-03-17 | Revance Therapeutics, Inc. (RVNC) Delisted | Tax (F) | −1,269 | -$24.4K | EDGAR |
| 2017-01-30 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +8,937 | -$21.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.